Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Archive
    • Upcoming Scientific Articles
  • Info for
    • Authors
    • Reviewers
    • Advertisers
    • Subscribers
  • About Us
    • About the North Carolina Medical Journal
    • Editorial Board
  • More
    • Alerts
    • Feedback
    • Help
    • RSS
  • Other Publications
    • North Carolina Medical Journal

User menu

  • My alerts
  • Log in

Search

  • Advanced search
North Carolina Medical Journal
  • Other Publications
    • North Carolina Medical Journal
  • My alerts
  • Log in
North Carolina Medical Journal

Advanced Search

  • Home
  • Content
    • Current
    • Archive
    • Upcoming Scientific Articles
  • Info for
    • Authors
    • Reviewers
    • Advertisers
    • Subscribers
  • About Us
    • About the North Carolina Medical Journal
    • Editorial Board
  • More
    • Alerts
    • Feedback
    • Help
    • RSS
  • Follow ncmj on Twitter
  • Visit ncmj on Facebook
Research ArticlePolicy Forum

Running the Numbers

Drug Expenditure Trends in North Carolina Medicaid

Allison E. Fay and Trista Pfeiffenberger
North Carolina Medical Journal May 2017, 78 (3) 208-211; DOI: https://doi.org/10.18043/ncm.78.3.208
Allison E. Fay
pharmacy practice resident, Community Care of North Carolina, Raleigh, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trista Pfeiffenberger
director, Network Pharmacy Programs, Community Care of North Carolina, Raleigh, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tpfeiffenberger@n3cn.org
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Rising drug prices have received a lot of attention in the past several years, but costs and trends within Medicaid programs vary from those in the commercially insured market. This article provides cost and trend information for the North Carolina Medicaid Outpatient Pharmacy Program over State fiscal years (SFYs) 2015-2016.

North Carolina Medicaid Outpatient Pharmacy Program

The North Carolina Medicaid Outpatient Pharmacy Program offers comprehensive drug coverage to ensure that low-income North Carolinians have medication access. Stakeholder collaboration, effective use of drug rebates, and careful selection of drugs from a Preferred Drug List (PDL) are just three ways the North Carolina Division of Medical Assistance provides access to medications at the most advantageous costs. The PDL, which was first implemented for North Carolina Medicaid in 2010, has allowed the state to achieve a higher percentage of savings for covered outpatient drugs through manufacturer rebates. The percentage of outpatient drug costs offset by manufacturer rebates has steadily increased over time [1, 2]. This has blunted the effect of rising drug costs to the state, leading to a situation where overall net drug costs have remained relatively constant over the most recent fiscal years. In total, post-rebate prescription costs across the state in fiscal year 2016 accounted for about 7% of total Medicaid costs in North Carolina [3].

For almost 30 years, federal legislation has mandated that drug manufacturers sign a rebate agreement with the US Department of Health and Human Services, guaranteeing a minimum Medicaid rebate in exchange for drug coverage by state Medicaid programs [4]. As drugs become available on the market, these drug rebates become an important component of determining how drugs are classified on the PDL in North Carolina. By federal law, when new brand name medications enter the market, a minimum rebate of 23.1% of the average manufacturer price (AMP) is required [4]. A Consumer Price Index for All Urban Consumers penalty may occur on top of the required federal rebate for brand name medications. This penalty is used to protect states against drug price inflation if a manufacturer raises its price faster than the rate of inflation. In addition, states may receive supplemental rebates that average 3%-6% of a state's gross spending, depending on state practices, including clinical criteria for prior approvals, reimbursement algorithms, and the drug mix on their PDL. When generic formulations become available, they are generally priced at a small discount of the brand's gross cost, with a fixed federal rebate at 13% of AMP. While generic products can become cost effective alternatives over time, factors affecting the availability of new generic drugs can cause the net cost to remain relatively high for months to years after initial market entry [4].

Figure 1 outlines the impact of rebates on the total net drug spending by North Carolina Medicaid. Rebate reimbursements were received for 52% of the total drug costs in 2015 and 59% in 2016 [5, 6]. These rebates were comparable to that of the federal rebate average, which in 2015 was 54% [4].

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

NC Medicaid Pre- and Post-Rebate Drug Costs SFY 2012-SFY 2016

It is important for state Medicaid programs to account for all of these factors that together contribute to the overall cost of a drug. While history may lead one to believe that generic medications are lower cost than their brand equivalents, an effective combination of federal and supplemental rebates offered through manufacturers can drive the net cost to the state lower for brand name products than the generic, allowing the brand name product to achieve preferred status on the PDL. In addition, the rising costs of generics over the last several years is a factor contributing to more brand name products becoming preferred agents on the PDL. Many factors influence the pricing of generic medications, and marketplace competition among generic manufacturers is a primary driver. A recent survey of multiple stakeholders in the drug supply chain indicated that rising generic drug prices are primarily due to manufacturer consolidation and raw material shortages [7, 8].

North Carolina Medicaid Drug Spending Costs

The North Carolina Medicaid population is broken down into various eligibility categories that contribute differently to overall drug spending. Table 1 outlines the total drug costs by program eligibility for Medicaid in SFY 2016. Children collectively make up over 50% of the total Medicaid population; however, children account for only about one-third of total drug costs [3, 9]. Looking more closely, children covered by the North Carolina Health Choice program, which provides coverage for beneficiaries who are children of families whose income is too high to qualify for traditional Medicaid but too low to afford private insurance, accounts for less than 5% of total Medicaid drug costs, yet comprises approximately one-third of total health care costs for Health Choice beneficiaries [3, 9].

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 1.

Total Drug Cost by Program Eligibility Category SFY 2016

On the other hand, while aged/blind/disabled beneficiaries make up only one-fifth of the total Medicaid population, about half of the total drug costs are from those beneficiaries, totaling just over $975 million in 2016 [3, 9].

Other Medicaid populations, including pregnant women, dually-eligible Medicare beneficiaries, refugees and foreign nationals, and other adult populations, such as family planning, together make up the remaining drug spending costs. These groups combined total about 17% of the total Medicaid drug costs in North Carolina [9].

In North Carolina, the net costs from the total Medicaid population for prescription claims have consistently decreased over the last two SFYs. Table 2 provides a summary of these costs across that timeframe. While there was a slight increase in the total payment amount from SFY 2015 to SFY 2016, the decreasing trend in net spending is largely driven by the increase in total rebate receipts from 52% in SFY 2015 to 59% in SFY 2016 [5, 6].

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 2.

Summary of Beneficiaries, Claims, and Costs SFY 2015-SFY 2016 [8, 9]

Drug Costs by Class

In discussing Medicaid drug costs, it is important to note trends seen among medications prescribed across this population. Table 3 outlines 10 prescription medications that over the last fiscal year have consistently been within the top 10 medications by cost.

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 3.

NC Medicaid Outpatient Pharmacy Program Top Ten Medication Expenditures by Cost (SFY 2016) [9]

These medications are typically used to treat behavioral health conditions, ADHD, hepatitis C, diabetes, and asthma. The cost of the drug itself, or the number of claims associated with more commonly prescribed medications, such as albuterol, can drive these agents to consistently appear in this list.

Some of the high cost agents for North Carolina Medicaid, specifically behavioral health medications such as Abilify and specialty drugs including Harvoni and Viekira (both to treat hepatitis C), also appeared in the top 10 drugs contributing to an increase in the net cost nationally to Medicaid programs in 2015, showing that these medications, while not prescribed to a high number of individuals, can drive up drug spending costs [4]. This trend also aligns with other national Medicaid spending reports. Per the 2015 Drug Trend Report published by Express Scripts, medications used in HIV, hepatitis C, and inflammatory diseases were the top therapy classes that continue to drive Medicaid specialty drug spending, accounting for two-thirds of the total costs for specialty drugs; specialty medications as a whole accounted for over one-third (36.5%) of total Medicaid drug costs in 2015 [10].

Conclusion

Medications are a mainstay in the treatment of many chronic illnesses. While many are focused on the rising costs of medications, little focus is paid to the improvements in health care utilization and outcomes that can be achieved from effective medication use. Within the proportion of North Carolina Medicaid beneficiaries enrolled with Community Care of North Carolina, higher drug expenditures are associated with improved rates of medication adherence, and along with higher utilization of primary care visits, have been shown to decrease hospitalizations and improve the total cost of care [11]. At just 7% of the overall Medicaid budget, medications can be considered a good investment to improve the overall health of North Carolina Medicaid beneficiaries.

Acknowledgments

The authors would like to acknowledge the NC Medicaid DUR Board and John Stancil, Director of Pharmacy and DMEPOS Programs with NC Division of Medical Assistance, for provision of data used in this article.

Potential conflicts of interest. A.E.F. and T.P. have no relevant conflicts of interest.

  • ©2017 by the North Carolina Institute of Medicine and The Duke Endowment. All rights reserved.

References

  1. ↵
    Preferred Drug List Review Panel. NC Division of Medical Assistance website. https://www2.ncdhhs.gov/DMA/pharmacy/pdl.htm. Accessed May 4, 2017.
  2. ↵
    1. North Carolina Division of Medical Assistance
    Outpatient Pharmacy Services. North Carolina Department of Health and Human Services website. https://dma.ncdhhs.gov/providers/programs-services/Prescription-drugs/Outpatient-Pharmacy-Services. Updated February 2017. Accessed March 9, 2017.
  3. ↵
    1. Sutton T,
    2. Borchik R
    Running the Numbers: An Overview of North Carolina Medicaid and Health Choice. N C Med J. 2017;78(1):58-62.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Magellan Rx Management
    2016 Medicaid Trend Report. https://www1.magellanrx.com/media/506517/medicaid_trendreport_2016_final.pdf. Accessed April 13, 2017.
  5. ↵
    1. Department of Medical Assistance (DMA)
    Presented at: North Carolina Drug Utilization Review Board Meeting; October 2015; Raleigh, NC.
  6. ↵
    1. Department of Medical Assistance (DMA)
    Presented at: The NC Medicaid DUR Board Meeting; October 27, 2016; Raleigh, NC.
  7. ↵
    1. Terry K
    Some Generic Drugs See Huge Price Increases. Medscape Medical News. http://www.medscape.com/viewarticle/868812. Published September 15, 2016. Accessed March 10, 2017.
  8. ↵
    1. Elsevier Clinical Solutions
    White Paper: The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain. http://www.ncpa.co/pdf/elsevier_wp_genericdrug.pdf. Published 2015. Accessed March 12, 2017.
  9. ↵
    1. Stancil J
    Drug Expenditures by Program Eligibility Category SFY2014 thru SFY2016 [Email]. Message to: Trista Pfeiffenberger. Sent February 14, 2017. Cited March 8, 2017.
  10. ↵
    1. The Express Scripts Lab
    Express Scripts 2015 Drug Trend Report. Published March 2016. Accessed March 8, 2017.
  11. ↵
    1. Treo Solutions
    Performance Analysis: Healthcare Utilization of CCNC-Enrolled Population 2007-2010. Community Care of North Carolina website. https://www.communitycarenc.org/media/related-downloads/treo-solutions-report-on-utilization.pdf. Published June 2012. Accessed March 10, 2017.
PreviousNext
Back to top

In this issue

North Carolina Medical Journal: 78 (3)
North Carolina Medical Journal
Vol. 78, Issue 3
May-June 2017
  • Table of Contents
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on North Carolina Medical Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Running the Numbers
(Your Name) has sent you a message from North Carolina Medical Journal
(Your Name) thought you would like to see the North Carolina Medical Journal web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Running the Numbers
Allison E. Fay, Trista Pfeiffenberger
North Carolina Medical Journal May 2017, 78 (3) 208-211; DOI: 10.18043/ncm.78.3.208

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Running the Numbers
Allison E. Fay, Trista Pfeiffenberger
North Carolina Medical Journal May 2017, 78 (3) 208-211; DOI: 10.18043/ncm.78.3.208
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • North Carolina Medicaid Outpatient Pharmacy Program
    • North Carolina Medicaid Drug Spending Costs
    • Drug Costs by Class
    • Conclusion
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Policy Forum

  • To Inspire Vaccination, Inspire Hope
  • A Vaccine for Society
  • Focus on Philanthropy : Investing in the Affordable Care Act and Expanding Medicaid are Critical to Statewide Health
Show more Policy Forum

DEPARTMENTS

  • Tar Heel Footprints in Health Care
  • Spotlight on the Safety Net: Deploying Mobile COVID-19 Testing Programs in North Carolina as an Approach to Improving Health Equity
  • Focus on Philanthropy : Investing in the Affordable Care Act and Expanding Medicaid are Critical to Statewide Health
Show more DEPARTMENTS

Similar Articles

About & Contact

  • About the NCMJ
  • Editorial Board
  • Feedback

Info for

  • Advertisers
  • Authors
  • Reviewers
  • Subscribers

Articles & Alerts

  • Archive
  • Current Issue
  • Get Alerts
  • Upcoming Articles

Additional Content

  • Current NCIOM Task Forces
  • NC Health Data & Resources
  • NCIOM Blog
North Carolina Medical Journal

ISSN: 0029-2559

© 2021 North Carolina Medical Journal

Powered by HighWire